Hemophilia A Pipeline Review, H1 2018 – ResearchAndMarkets.com

The “Hemophilia
A – Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s

Hemophilia A – Pipeline Review, H1 2018, provides comprehensive
information on the therapeutics under development for Hemophilia A
(Hematological Disorders), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews
of key players involved in therapeutic development for Hemophilia A and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Pre-Registration, Phase III,
Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10,
7, 4, 24, 3 and 2 respectively. Similarly, the Universities portfolio in
Phase II and Preclinical stages comprises 1 and 3 molecules,

Hemophilia A (Hematological Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Key Topics Covered:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/rgbmt4/hemophilia_a?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618006128/en/